person · Reporting owner
Reveles Xavier Trinidad
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| bioAffinity Technologies, Inc.BIAF · Entity 8368 | Chief Operating Officer | January 10, 2025 | January 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
bioAffinity Technologies, Inc.
Report date January 10, 2025 · Filed January 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,943 |
Reported balance
After 2025-01-10 transaction · row 1
1 source rowRow 1 · 2025-01-10 · Grant · Acquired 21,604 · Balance 41,943 F1: Grant of restricted shares of common stock that vest pro rata on a monthly basis for 12 months commencing on February 10, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted shares of common stock that vest pro rata on a monthly basis for 12 months commencing on February 10, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 10, 2025 Filed Jan 14, 2025 21:15 UTC | bioAffinity Technologies, Inc. BIAF · Entity 8368 | GrantCommon Stock | 21,604 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-002149 · ownership.xml · nonDerivative · entry 1 Reveles Xavier Trinidad · CIK 0001993507 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,943 F1 · shares: Grant of restricted shares of common stock that vest pro rata on a monthly basis for 12 months commencing on February 10, 2025. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:22 UTC | bioAffinity Technologies, Inc. BIAF · Entity 8368 | GrantCommon Stock | 16,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-004764 · ownership.xml · nonDerivative · entry 1 Reveles Xavier Trinidad · CIK 0001993507 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,339 F1 · shares: Grant of restricted shares, which shares will vest pro rata on a monthly basis for 12 months commencing on February 29, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.